Infinity Pharmaceuticals, Inc. stock performance trend indicates that the stock price has rallied 157.25% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 127.56% . Looking at the past 52 week period, the stock price is down -44.01% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Infinity Pharmaceuticals, Inc. has a negative value of -64.31 compared to overall market performance.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 74.97.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has climbed 18.73% in the past week and advanced 45.49% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 18.45% and the outperformance has advanced to 43.84% for the last 4 weeks period.
Company shares have received an average consensus rating of Hold for the current week Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) : On Friday heightened volatility was witnessed in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) which led to swings in the share price. The stock opened for trading at $3.24 and hit $3.55 on the upside , eventually ending the session at $3.55, with a gain of 9.23% or 0.3 points. The heightened volatility saw the trading volume jump to 1,852,262 shares. The 52-week high of the share price is $6.63 and the company has a market cap of $179 million. The 52-week low of the share price is at $0.8402 .
Company has reported several Insider transactions to the SEC, on Dec 14, 2016, Sujay Kango (Chief Commercial Officer) sold 75,000 shares at 1.28 per share price.On Jun 26, 2015, Adelene Q Perkins (President & CEO) sold 5,000 shares at 10.93 per share price.On Jun 16, 2015, Vito J. Palombella (Chief Scientific Officer) sold 4,737 shares at 10.97 per share price.
Infinity Pharmaceuticals Last issued its quarterly earnings results on Mar 14, 2017. The company reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $-0.49.Analysts expectations of $ 2.33.The companys revenue was down -100.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.80 EPS.
Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.